Vaxart Offers Advantages With VXA-CoV2-1: An Approved Vaccine Is Just The Beginning
VXRT

Vaxart, Inc. ($VXRT) continues to attract attention thanks to its oral covid-19 vaccine candidate called VXA-CoV2-1, which lately is paying off in green numbers again. As an FDA-approved corona vaccine approaches, attention is increasingly shifting to the logistics issue, where the transportation of non-oral vaccine candidates faces serious difficulties. An approved vaccine is just the…